No Data
No Data
SANAI HEALTH GP: Annual Report 2024
《Performance》SANAI HEALTH GP (01889.HK) had an annual net profit of 4.892 million RMB, a decrease of 73.7%. The auditor issued a qualified opinion.
SANAI HEALTH GP (01889.HK) announced its annual results for the year ending last December, with Business revenue of 85.217 million yuan (RMB, the same below), a year-on-year decrease of 20.9%. Net profit was 4.892 million yuan, down 73.7% year on year; earnings per share were 3.37 cents. No dividend was declared. The independent auditor expressed a qualified opinion.
SANAI HEALTH GP (01889) announced its annual performance, with Shareholder attributable profit of 4.892 million yuan, a decrease of 73.75% year-on-year.
SANAI HEALTH GP (01889) announced its annual performance for the year ending December 31, 2024, with the group achieving revenue...
SANAI HEALTH GP: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 DECEMBER 2024
SANAI HEALTH GP (01889.HK) will hold a Board of Directors meeting on March 31 to approve the annual performance.
On March 14, Gelonghui announced that SANAI HEALTH GP (01889.HK) will hold a Board of Directors meeting on March 31, 2025, to approve the annual performance announcement for the year ending December 31, 2024, for the company and its subsidiaries.
All the way up! The Innovative Drugs Sector in Hong Kong stocks surged collectively, with multiple stocks doubling this year. Who is reshaping the valuation?
The rise in the Hong Kong stock market's Innovative Drugs Sector continues. Market analysts point out that this wave of Innovative Drugs momentum benefits from a combination of factors including market sentiment, policy, and the realization of the companies' own commercial value.